Brandon Webb
Internal Medicine · Salt Lake City, UTNPI 1750540522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by MML US, Inc. at 58.6% of the total. 2025 is the largest year on record at $219, 3.7 times the $59 reported in 2022.
Across 6 payments — averaging $62.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MML US, Inc.$219
- Boston Scientific$93
- AbbVie$29
- Insmed, Inc.$16
- Gilead$14
- Intuitive Surgical$3
Across 16 payments — averaging $33,973 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$423K
- Regeneron$113K
- Astellas Pharma Global Development$8K
What the payments were for
- Food & beverage$34392%
- Education$308%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MML US, Inc. | 1 | $219 |
| Boston Scientific | 1 | $93 |
| AbbVie | 1 | $29 |
| Insmed, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| Intuitive Surgical | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ReActiv8$219
How this compares
$373 in reported general payments places this provider in the 65th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 15 | $1,902 |
| Cephalexin | 11 | $1,009 |
| Methenamine Hippurate | 14 | $853 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $415 |
| Cefazolin Sodium | 23 | $374 |
| CeftriaxoneCeftriaxone Sodium | 17 | $213 |
| Fluconazole | 16 | $191 |
| Clindamycin Hcl | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Salt Lake City
- Willard DereSalt Lake City$4.7M
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Gerald GleichSalt Lake City$22K
- Brian HornerSalt Lake City$21K
- Rachel HessSalt Lake City$18K
- Linda VennerSalt Lake City$8K
- David KuoSalt Lake City$8K
- Evan DaughertySalt Lake City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.